NASDAQ:PHIO
Phio Pharmaceuticals Corp. Stock News
$0.581
-0.0293 (-4.80%)
At Close: Jul 03, 2024
Phio Pharmaceuticals Announces Reverse Stock Split
11:45am, Tuesday, 02'nd Jul 2024
Marlborough, Massachusetts--(Newsfile Corp. - July 2, 2024) - Phio Pharmaceuticals Corp. (Nasdaq: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene s
Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging
07:30am, Tuesday, 18'th Jun 2024
Phio's Compound RXI-185 is designed to slow progression of UV induced collagen breakdown Marlborough, Massachusetts--(Newsfile Corp. - June 18, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a cli
Intratumoral PH-762 has encouraging safety profile in the initial cohort Escalation to proceed to next dose concentration Marlborough, Massachusetts--(Newsfile Corp. - May 28, 2024) - Phio Pharmaceuti
Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
05:00pm, Thursday, 23'rd May 2024
Phio to present a clinical study progress update on their lead clinical candidate, PH-762 Marlborough, Massachusetts--(Newsfile Corp. - May 23, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a cli
Phio Pharmaceuticals Secures New Investor
09:00am, Friday, 17'th May 2024
MARLBOROUGH, Mass., May 17, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is d
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
01:00pm, Wednesday, 15'th May 2024
- PH-762 is Phio's lead product candidate -Screening on the next cohort is on-going MARLBOROUGH, Mass., May 15, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage bio
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
05:25pm, Thursday, 09'th May 2024
–Four sites across the country participating in Phase 1b clinical trial for lead product candidate PH-762 – Three patients have been enrolled MARLBOROUGH, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- P
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
07:30am, Tuesday, 30'th Apr 2024
-Phio's lead clinical product candidate, PH-762, is the focus of dermatological poster presentation -Phio's lead clinical product candidate, PH-762, is the focus of dermatological poster presentation
-Injection in murine tumors shows the compound is well tolerated -Studies support ongoing clinical trial of PH-762 as a neoadjuvant therapy for treatment of cSCC, melanoma, or Merkel cell carcinoma MA
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
07:30am, Tuesday, 16'th Apr 2024
Phio's lead clinical product candidate, PH-762, is the subject of three new dermatological posters Phio's lead clinical product candidate, PH-762, is the subject of three new dermatological posters
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
07:30am, Thursday, 11'th Apr 2024
MARLBOROUGH, Mass., April 11, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is
National Spotlight Features Phio's Innovative RNAi Technology Platform
07:30am, Wednesday, 03'rd Apr 2024
—Program will be airing on PBS with Dennis Quaid in April —It will also be seen on Fox Business Network MARLBOROUGH, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: P
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
07:30am, Tuesday, 02'nd Apr 2024
– Four sites across the country participating in clinical trial for lead product candidate PH-762 – Two patients have already completed treatment – New patent granted for skin related treatmen
MARLBOROUGH, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is
Phio's Compound RXI-185 and RXI-231 designed to treat photo-aging and hyperpigmentation Phio's Compound RXI-185 and RXI-231 designed to treat photo-aging and hyperpigmentation